Announced
Synopsis
AstraZeneca, a pharmaceutical company, agreed to acquire LaNova Medicines, a clinical-stage innovative drug research and development company. Financial terms were not disclosed. “LaNova Medicines has a strong focus on discovering and developing innovative medicines in the ADC and immuno-oncology fields. We’re excited to reach this agreement with AstraZeneca," Crystal Qin, LaNova Medicines Founder, Chair and CEO.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
Seller Team (4)
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
All rights reserved. Copyright © 2025 Datasite